OncoMatch/Clinical Trials/NCT04307576
A Treatment Study Protocol for Participants 0-45 Years With Acute Lymphoblastic Leukaemia
Is NCT04307576 recruiting? Yes, currently enrolling (May 2026). This Phase 3 trial studies multiple treatments for leukemia, acute lymphoblastic.
Treatment: Omitted Doxorubicin · Omitted Vincristine+Dexamethasone pulses · Inotuzumab Ozogamicin+Standard Maintenance Therapy · Imatinib · 6-tioguanine+Standard Maintenance Therapy · Blinatumomab — ALLTogether collects the experience of previously successful treatment of infants, children and young adults, with ALL from a number of well-renowned study groups into a new master protocol, which is both a comprehensive system for stratification and treatment of ALL in this age-group as well as the basis for several randomised and interventional trials included in the study-design.
Check if I qualifyExtracted eligibility criteria
Cancer type
Acute Lymphoblastic Leukemia
Biomarker criteria
Excluded: KMT2A (MLL) rearrangement
Age < 365 days and KMT2A-rearranged (KMT2A-r) BCP-ALL (documented presence of a KMT2A-split by FISH and/or a KMT2A fusion transcript)
Excluded: BCR ABL fusion
Patients with Ph-positive ALL (documented presence of t(9;22)(q34;q11) and/or of the BCR::ABL fusion transcript)
Excluded: BCL2 rearrangement
any patients with IG::MYC and a concurrent BCL2/6 rearrangement
Excluded: BCL6 rearrangement
any patients with IG::MYC and a concurrent BCL2/6 rearrangement
Excluded: ETV6 germline mutation
germline ETV6 mutation
Allowed: MYC rearrangement
Patients with surface immunoglobulin negative (sIG-) BCP-ALL and an IG::MYC rearrangement, unless they have a concurrent BCL2/6 rearrangement. T-ALL patients with MYC translocations.
Prior therapy
Cannot have received: systemic corticosteroids
Treatment with systemic corticosteroids corresponding to (>10mg prednisolone/m2/day) for more than one week and/or other chemotherapeutic agents in a 4-week interval prior to diagnosis (pre-treatment)
Cannot have received: chemotherapy
other chemotherapeutic agents in a 4-week interval prior to diagnosis (pre-treatment)
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify